Literature DB >> 10740329

Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users.

T Backman1, S Huhtala, T Blom, R Luoto, I Rauramo, M Koskenvuo.   

Abstract

OBJECTIVE: To establish the continuation rates of the levonorgestrel intrauterine system (LNG IUS) and symptoms associated with its premature removal. SAMPLE AND
SETTING: All women in Finland who had a LNG IUS inserted between April 1990 and December 1993 and whose doctor had filled in and returned a form at the insertion visit. This study population consists of 46% of all the LNG IUSs sold in Finland between 1990 and 1993.
DESIGN: A questionnaire on reproductive and contraceptive history, gynaecological problems and symptoms experienced during the use of the LNG IUS was sent to 23,885 LNG IUS users. A total of 17,914 questionnaires were returned (response rate 75%). The results cover experience from 58,600 woman years. A log-rank-test was used to test differences in continuation rates. Multivariate analyse were performed using Cox's proportional hazard model.
RESULTS: The LNG IUS was prematurely removed from 5175 women. The one, two, three, four and five year continuation rates were 93%, 87%, 81%, 75% and 65%, respectively. The symptoms during the use of the LNG IUS most strongly associated with its premature removal were excessive bleeding and spotting, and infections and pain. The risk of premature removal was markedly lower among women who had occasional or total absence of menstruation. Premature removal was less likely in the oldest age group.
CONCLUSIONS: The continuation rate of the LNG IUS compares favourably with other long-acting contraceptive systems. Totally or occasionally absent menstruation was strongly associated with prolonged continuation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740329     DOI: 10.1111/j.1471-0528.2000.tb13228.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  12 in total

1.  Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.

Authors:  Megan A Cohen; Katharine B Simmons; Alison B Edelman; Jeffrey T Jensen
Journal:  Contraception       Date:  2019-06-18       Impact factor: 3.375

2.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

3.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Cost effectiveness of contraceptives in the United States.

Authors:  James Trussell; Anjana M Lalla; Quan V Doan; Eileen Reyes; Lionel Pinto; Joseph Gricar
Journal:  Contraception       Date:  2008-09-25       Impact factor: 3.375

Review 5.  Benefits and risks of pharmacological agents used for the treatment of menorrhagia.

Authors:  Samendra Nath Roy; Siladitya Bhattacharya
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

7.  True Mirena failure: Twin pregnancy with Mirena in situ.

Authors:  Jyoti Kumari; Sonia Malik; Meenakshi Dua
Journal:  J Midlife Health       Date:  2013-01

8.  Experience and levels of satisfaction with the levonorgestrel-releasing intrauterine system in China: a prospective multicenter survey.

Authors:  Shuping Zhao; Jihong Deng; Yan Wang; Shiliang Bi; Xiaoye Wang; Wen Qin; Zirong Huang; Li Li; Xin Mi; Liping Han; Qing Chang; Jian Li
Journal:  Patient Prefer Adherence       Date:  2014-10-23       Impact factor: 2.711

9.  Do Progestin-Only Contraceptives Contribute to the Risk of Developing Depression as Implied by Beta-Arrestin 1 Levels in Leukocytes? A Pilot Study.

Authors:  Keisha Smith; Sanket Nayyar; Tanu Rana; Anthony E Archibong; Kimberly R Looney; Tultul Nayyar
Journal:  Int J Environ Res Public Health       Date:  2018-09-09       Impact factor: 3.390

10.  Comparing options for females seeking permanent contraception in high resource countries: a systematic review.

Authors:  Rebecca Gormley; Brian Vickers; Brooke Cheng; Wendy V Norman
Journal:  Reprod Health       Date:  2021-07-20       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.